UroGen Pharma Ltd. (NASDAQ:URGN) will hold its 3Q20 earnings conference call with the financial community on 9th November 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at www.urogen.com
Earnings Expectation
UroGen Pharma Ltd. is set to announce third quarter earning results on Monday 9th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, URGN to report 3Q20 loss of $ 1.49 per share from revenue of $ 3.34 million. For the full year, analysts anticipate top line of $ 11.79 million, while looking forward to loss of $ 6.16 per share bottom line.
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The companys lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.
